{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:53:05Z","timestamp":1793040785766,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/nrclinonc.2010.21","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T16:24:26Z","timestamp":1268756666000},"page":"209-219","source":"Crossref","is-referenced-by-count":377,"title":["mTOR signaling and drug development in cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"Janet","family":"Dancey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,16]]},"reference":[{"key":"BFnrclinonc201021_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ceb.2009.01.016","volume":"21","author":"HA Lane","year":"2009","unstructured":"Lane, H. A. & Breuleux, M. Optimal targeting of the mTORC1 kinase in human cancer. Curr. Opin. Cell Biol. 21, 219\u2013229 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrclinonc201021_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1517\/14728222.12.2.209","volume":"12","author":"RT Abraham","year":"2008","unstructured":"Abraham, R. T. & Eng, C. H. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets 12, 209\u2013222 (2008).","journal-title":"Expert Opin. Ther. Targets"},{"key":"BFnrclinonc201021_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","volume":"1784","author":"R Marone","year":"2008","unstructured":"Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784, 159\u2013185 (2008).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrclinonc201021_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara, K. et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177\u2013189 (2002).","journal-title":"Cell"},{"key":"BFnrclinonc201021_CR5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296\u20131302 (2004).","journal-title":"Curr. Biol."},{"key":"BFnrclinonc201021_CR6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-08-3014","volume":"69","author":"J Copp","year":"2009","unstructured":"Copp, J., Manning, G. & Hunter, T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821\u20131827 (2009).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR7","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","volume":"7","author":"JA Garcia","year":"2008","unstructured":"Garcia, J. A. & Danielpour, D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol. Cancer Ther. 7, 1347\u20131354 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc201021_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/BST0370217","volume":"37","author":"J Huang","year":"2009","unstructured":"Huang, J. & Manning, B. D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217\u2013222 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrclinonc201021_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","volume":"14","author":"OJ Shah","year":"2004","unstructured":"Shah, O. J., Wang, Z. & Hunter, T. Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650\u20131656 (2004).","journal-title":"Curr. Biol."},{"key":"BFnrclinonc201021_CR10","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065\u20133074 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201021_CR11","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccr.2004.05.027","volume":"5","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti, M. A. & Houghton, P. J. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5, 519\u2013523 (2004).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201021_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335\u2013348 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201021_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671\u2013688 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201021_CR15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/cncr.24239","volume":"115","author":"GR Hudes","year":"2009","unstructured":"Hudes, G. R. Targeting mTOR in renal cell carcinoma. Cancer 115, 2313\u20132320 (2009).","journal-title":"Cancer"},{"key":"BFnrclinonc201021_CR16","first-page":"6141","volume":"62","author":"V Gr\u00fcnwald","year":"2002","unstructured":"Gr\u00fcnwald, V. et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62, 6141\u20136145 (2002).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1023\/B:APPT.0000045781.46314.e2","volume":"9","author":"D Aguirre","year":"2004","unstructured":"Aguirre, D. et al. Bcl-2 and CCND1\/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9, 797\u2013805 (2004).","journal-title":"Apoptosis"},{"key":"BFnrclinonc201021_CR18","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","volume":"10","author":"LA deGraffenried","year":"2004","unstructured":"deGraffenried, L. A. et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 10, 8059\u20138067 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR19","first-page":"68","volume-title":"ASCO Educational Book 2000","author":"J Dancey","year":"2000","unstructured":"Dancey, J. in ASCO Educational Book 2000 68\u201375 (Lippincott Williams & Wilkins, Alexandria, Virginia, 2000)."},{"key":"BFnrclinonc201021_CR20","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","volume":"69","author":"K Yu","year":"2009","unstructured":"Yu, K. et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232\u20136240 (2009).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","volume":"8","author":"M Breuleux","year":"2009","unstructured":"Breuleux, M. et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition. Mol. Cancer Ther. 8, 742\u2013753 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc201021_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128\u2013135 (2002).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201021_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1006\/bbrc.2001.4981","volume":"28","author":"H Zhong","year":"2001","unstructured":"Zhong, H., Hanrahan, C., van der Poel, H. & Simons, J. W. Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. Biochem. Biophys. Res. Commun. 28 4, 352\u2013356 (2001).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrclinonc201021_CR24","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong, H. et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541\u20131545 (2000).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","volume":"1","author":"LM Ballou","year":"2008","unstructured":"Ballou, L. M. & Lin, R. Z. Rapamycin and mTOR kinase inhibitors. J. Chem. Biol. 1, 27\u201336 (2008).","journal-title":"J. Chem. Biol."},{"key":"BFnrclinonc201021_CR26","first-page":"8451","volume":"63","author":"AL Edinger","year":"2003","unstructured":"Edinger, A. L., Linardic, C. M., Chiang, G. G., Thompson, C. B. & Abraham, R. T. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63, 8451\u20138460 (2003).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol. Cell 22, 159\u2013168 (2006).","journal-title":"Mol. Cell"},{"key":"BFnrclinonc201021_CR28","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","volume":"5","author":"TF Cloughesy","year":"2008","unstructured":"Cloughesy, T.F. et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8 (2008).","journal-title":"PLoS Med."},{"key":"BFnrclinonc201021_CR29","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","volume":"68","author":"B Shor","year":"2008","unstructured":"Shor, B. et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 68, 2934\u20132943 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.4161\/cc.8.7.8044","volume":"8","author":"DA Foster","year":"2009","unstructured":"Foster, D. A. & Toschi, A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 8, 1026\u20131029 (2009).","journal-title":"Cell Cycle"},{"key":"BFnrclinonc201021_CR31","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O'Donnell","year":"2008","unstructured":"O'Donnell, A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26, 1588\u20131595 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero, J. et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26, 1603\u20131610 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR33","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","volume":"25","author":"M Fouladi","year":"2007","unstructured":"Fouladi, M. et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J. Clin. Oncol. 25, 4806\u20134812 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR34","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess, G. et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27, 3822\u20133829 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR35","doi-asserted-by":"crossref","first-page":"a3513","DOI":"10.1200\/jco.2007.25.18_suppl.3513","volume":"25","author":"S Ellard","year":"2007","unstructured":"Ellard, S. et al. A randomized phase II study of two different schedules of RAD001C in patients with recurrent\/metastatic breast cancer [abstract]. J. Clin. Oncol. 25, a3513 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR36","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","volume":"22","author":"E Raymond","year":"2004","unstructured":"Raymond, E. et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22, 2336\u20132347 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR37","first-page":"1527","volume":"61","author":"B Geoerger","year":"2001","unstructured":"Geoerger, B. et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61, 1527\u20131532 (2001).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/00007691-200010000-00006","volume":"22","author":"C Brattstr\u00f6m","year":"2000","unstructured":"Brattstr\u00f6m, C. et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther. Drug Monit. 22, 537\u2013544 (2000).","journal-title":"Ther. Drug Monit."},{"key":"BFnrclinonc201021_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/FTD.0b013e31816ba73a","volume":"30","author":"G Filler","year":"2008","unstructured":"Filler, G., Bendrick-Peart, J. & Christians, U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther. Drug Monit. 30, 138\u2013142 (2008).","journal-title":"Ther. Drug Monit."},{"key":"BFnrclinonc201021_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner, G. I., Meier-Wiedenbach, I. & Manns, M. P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43, 83\u201395 (2004).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrclinonc201021_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/jlts.2001.24645","volume":"7","author":"P Neuhaus","year":"2001","unstructured":"Neuhaus, P., Klupp, J. & Langrehr, J. M. mTOR inhibitors: an overview. Liver Transpl. 7, 473\u2013484 (2001).","journal-title":"Liver Transpl."},{"key":"BFnrclinonc201021_CR42","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","volume":"42","author":"I Duran","year":"2006","unstructured":"Duran, I. et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur. J. Cancer 42, 1875\u20131880 (2006).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc201021_CR43","first-page":"a2000","volume":"40","author":"JJ Gibbons","year":"1999","unstructured":"Gibbons, J. J. et al. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc. Ame. Assoc. Cancer Res. 40, a2000 (1999).","journal-title":"Proc. Ame. Assoc. Cancer Res."},{"key":"BFnrclinonc201021_CR44","first-page":"a882","volume":"22","author":"T Clackson","year":"2003","unstructured":"Clackson, T. et al. Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development [abstract]. Proc. Am. Soc. Clin. Oncol. 22, a882 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BFnrclinonc201021_CR45","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449\u2013456 (2008).","journal-title":"Lancet"},{"key":"BFnrclinonc201021_CR46","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271\u20132281 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrclinonc201021_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00003495-200868001-00003","volume":"68","author":"A Kapoor","year":"2008","unstructured":"Kapoor, A. Malignancy in kidney transplant recipients. Drugs 68 (Suppl. 1), 11\u201319 (2008).","journal-title":"Drugs"},{"key":"BFnrclinonc201021_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/TP.0b013e318193886e","volume":"87","author":"AP Monaco","year":"2009","unstructured":"Monaco, A. P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 87, 157\u2013163 (2009).","journal-title":"Transplantation"},{"key":"BFnrclinonc201021_CR49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4161\/cc.8.3.7555","volume":"8","author":"VP Krymskaya","year":"2009","unstructured":"Krymskaya, V. P. & Goncharova, E. A. PI3K\/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 8, 403\u2013413 (2009).","journal-title":"Cell Cycle"},{"key":"BFnrclinonc201021_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1042\/BST0370259","volume":"37","author":"JR Sampson","year":"2009","unstructured":"Sampson, J. R. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem. Soc. Trans. 37, 259\u2013264 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrclinonc201021_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140\u2013151 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201021_CR52","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJMc072500","volume":"358","author":"DM Davies","year":"2008","unstructured":"Davies, D. M. et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 358, 200\u2013203 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201021_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncponc1112","volume":"5","author":"DJ Marsh","year":"2008","unstructured":"Marsh, D. J. et al. Rapamycin treatment for a child with germline PTEN mutation. Nat. Clin. Pract. Oncol. 5, 357\u2013361 (2008).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"BFnrclinonc201021_CR54","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","volume":"66","author":"D Del Bufalo","year":"2006","unstructured":"Del Bufalo, D. et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66, 5549\u20135554 (2006).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR55","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","volume":"111","author":"J Dal Col","year":"2008","unstructured":"Dal Col, J. et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111, 5142\u20135151 (2008).","journal-title":"Blood"},{"issue":"Suppl. 2","key":"BFnrclinonc201021_CR56","first-page":"a1081","volume":"94","author":"E Witzig","year":"2009","unstructured":"Witzig, E. et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed non-hodgkin lymphoma (NHL) and Hodgkin Disease (HD) [abstract]. Haematologica 94 (Suppl. 2), a1081 (2009).","journal-title":"Haematologica"},{"key":"BFnrclinonc201021_CR57","doi-asserted-by":"publisher","first-page":"a8514","DOI":"10.1200\/jco.2008.26.15_suppl.8514","volume":"26","author":"SM Smith","year":"2008","unstructured":"Smith, S. M. et al. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes [abstract]. J. Clin. Oncol. 26, a8514 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR58","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"2","author":"TE Witzig","year":"2005","unstructured":"Witzig, T. E. et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 2 3, 5347\u20135356 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR59","doi-asserted-by":"crossref","first-page":"a2732","DOI":"10.1200\/jco.2006.24.18_suppl.7532","volume":"24","author":"SM Ansell","year":"2006","unstructured":"Ansell, S. M. et al. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group [abstract]. J. Clin. Oncol. 24, a2732 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR60","doi-asserted-by":"crossref","first-page":"a3003","DOI":"10.1200\/jco.2006.24.18_suppl.3003","volume":"2","author":"AM Oza","year":"2006","unstructured":"Oza, A. M. et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer--NCIC IND 160 [abstract]. J. Clin. Oncol. 2 4, a3003 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR61","doi-asserted-by":"crossref","first-page":"a9505","DOI":"10.1200\/jco.2006.24.18_suppl.9505","volume":"24","author":"SP Chawla","year":"2006","unstructured":"Chawla, S. P. et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas [abstract]. J. Clin. Oncol. 24, a9505 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR62","doi-asserted-by":"crossref","first-page":"a9504","DOI":"10.1200\/jco.2006.24.18_suppl.9504","volume":"24","author":"SH Okuno","year":"2006","unstructured":"Okuno, S. H. et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS) [abstract]. J. Clin. Oncol. 24, a9504 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR63","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","volume":"95","author":"I Duran","year":"2006","unstructured":"Duran, I. et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95, 1148\u20131154 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201021_CR64","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, J. C. et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 26, 4311\u20134318 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR65","doi-asserted-by":"publisher","first-page":"a5516","DOI":"10.1200\/jco.2008.26.15_suppl.5516","volume":"26","author":"AM Oza","year":"2008","unstructured":"Oza, A. M. et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and\/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b [abstract]. J. Clin. Oncol. 26, a5516 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR66","doi-asserted-by":"crossref","first-page":"a5516","DOI":"10.1200\/jco.2007.25.18_suppl.5516","volume":"25","author":"N Colombo","year":"2007","unstructured":"Colombo, N. et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer [abstract]. J. Clin. Oncol. 25, a5516 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR67","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0b013e318155a439","volume":"2","author":"KJ Pandya","year":"2007","unstructured":"Pandya, K. J. et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J. Thorac. Oncol. 2, 1036\u20131041 (2007).","journal-title":"J. Thorac. Oncol."},{"key":"BFnrclinonc201021_CR68","doi-asserted-by":"publisher","first-page":"a19017","DOI":"10.1200\/jco.2008.26.15_suppl.19017","volume":"26","author":"TK Owonikoko","year":"2008","unstructured":"Owonikoko, T. K. et al. Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC) [abstract]. J. Clin. Oncol. 26, a19017 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR69","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","volume":"20","author":"JC Soria","year":"2009","unstructured":"Soria, J. C. et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann. Oncol. 20, 1674\u20131681 (2009).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc201021_CR70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","volume":"27","author":"BM Wolpin","year":"2009","unstructured":"Wolpin, B. M. et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 27, 193\u2013198 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR71","doi-asserted-by":"crossref","first-page":"a4612","DOI":"10.1200\/jco.2009.27.15_suppl.4612","volume":"27","author":"I Garrido-Laguna","year":"2009","unstructured":"Garrido-Laguna, I. et al. Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine [abstract]. J. Clin. Oncol. 27, a4612 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR72","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/cncr.21265","volume":"104","author":"K Margolin","year":"2005","unstructured":"Margolin, K. et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104, 1045\u20131048 (2005).","journal-title":"Cancer"},{"key":"BFnrclinonc201021_CR73","doi-asserted-by":"publisher","first-page":"a8530","DOI":"10.1200\/JCO.2007.10.8167","volume":"25","author":"RD Rao","year":"2007","unstructured":"Rao, R. D. et al. N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma [abstract]. J. Clin. Oncol. 25, a8530 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR74","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang, S. M. et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23, 357\u2013361 (2005).","journal-title":"Invest. New Drugs"},{"key":"BFnrclinonc201021_CR75","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"2","author":"E Galanis","year":"2005","unstructured":"Galanis, E. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2 3, 5294\u20135304 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR76","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","volume":"14","author":"DA Rizzieri","year":"2008","unstructured":"Rizzieri, D. A. et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 14, 2756\u20132762 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR77","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee, K. W. et al. Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 12, 5165\u20135173 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR78","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1158\/1078-0432.CCR-08-2076","volume":"15","author":"CM Hartford","year":"2009","unstructured":"Hartford, C. M. et al. A Phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res. 15, 1428\u20131434 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR79","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","volume":"12","author":"M Hidalgo","year":"2006","unstructured":"Hidalgo, M. et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12, 5755\u20135763 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR80","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","volume":"26","author":"MM Mita","year":"2008","unstructured":"Mita, M. M. et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26, 361\u2013367 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR81","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1200\/JCO.2008.18.8383","volume":"27","author":"WW Ma","year":"2009","unstructured":"Ma, W. W. et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J. Clin. Oncol. 27, 2697\u20132704 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR82","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/sj.bjc.6605076","volume":"100","author":"D Cejka","year":"2009","unstructured":"Cejka, D. et al. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br. J. Cancer 100, 1739\u20131745 (2009).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201021_CR83","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1073\/pnas.0806514106","volume":"10","author":"HB Salvesen","year":"2009","unstructured":"Salvesen, H. B. et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl Acad. Sci. USA 10 6, 4834\u20134839 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201021_CR84","unstructured":"Lane, H. The potential of mTOR inhibitors for the treatment of human cancers [abstract]. AACR Meeting Abstracts 2007, SY21\u201301 (2007)."},{"key":"BFnrclinonc201021_CR85","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","volume":"14","author":"PC Manegold","year":"2008","unstructured":"Manegold, P. C. et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 14, 892\u2013900 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR86","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1158\/1078-0432.CCR-08-1019","volume":"15","author":"JD Murphy","year":"2009","unstructured":"Murphy, J. D. et al. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin. Cancer Res. 15, 589\u2013596 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR87","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117\u2013127 (2004).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201021_CR88","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.2741\/2925","volume":"13","author":"AJ Casa","year":"2008","unstructured":"Casa, A. J., Dearth, R. K., Litzenburger, B. C., Lee, A. V. & Cui, X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front. Biosci. 13, 3273\u20133287 (2008).","journal-title":"Front. Biosci."},{"key":"BFnrclinonc201021_CR89","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","volume":"13","author":"CH Lu","year":"2007","unstructured":"Lu, C. H. et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res. 13, 5883\u20135888 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201021_CR90","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bcp.2009.04.033","volume":"78","author":"S La Monica","year":"2009","unstructured":"La Monica, S. et al. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem. Pharmacol. 78, 460\u2013468 (2009).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrclinonc201021_CR91","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11060-009-9950-0","volume":"96","author":"DA Reardon","year":"2010","unstructured":"Reardon, D. A. et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 96, 219\u2013230 (2010).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc201021_CR92","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-008-9741-z","volume":"92","author":"TN Kreisl","year":"2009","unstructured":"Kreisl, T. N. et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 92, 99\u2013105 (2009).","journal-title":"J. Neurooncol."},{"key":"BFnrclinonc201021_CR93","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004\u20137014 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrclinonc201021_CR94","first-page":"5173","volume":"63","author":"N El-Hashemite","year":"2003","unstructured":"El-Hashemite, N., Walker, V., Zhang, H. & Kwiatkowski, D. J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63, 5173\u20135177 (2003).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201021_CR95","doi-asserted-by":"publisher","first-page":"a16020","DOI":"10.1200\/jco.2008.26.15_suppl.16020","volume":"26","author":"P Fischer","year":"2008","unstructured":"Fischer, P. et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma [abstract]. J. Clin. Oncol. 26, a16020 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR96","doi-asserted-by":"publisher","first-page":"a14603","DOI":"10.1200\/jco.2008.26.15_suppl.14603","volume":"26","author":"S Giessinger","year":"2008","unstructured":"Giessinger, S. et al. A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC) [abstract]. J. Clin. Oncol. 26, a14603 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR97","doi-asserted-by":"crossref","first-page":"a5034","DOI":"10.1200\/jco.2007.25.18_suppl.5034","volume":"25","author":"JR Merchan","year":"2007","unstructured":"Merchan, J. R. et al. Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results [abstract]. J. Clin. Oncol. 25, a5034 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR98","doi-asserted-by":"crossref","first-page":"a3512","DOI":"10.1200\/jco.2007.25.18_suppl.3512","volume":"2","author":"A Patnaik","year":"2007","unstructured":"Patnaik, A. et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract]. J. Clin. Oncol. 2 5, a3512 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR99","doi-asserted-by":"publisher","first-page":"a5109","DOI":"10.1200\/jco.2008.26.15_suppl.5109","volume":"26","author":"JE Rosenberg","year":"2008","unstructured":"Rosenberg, J. E. et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract]. J. Clin. Oncol. 26, a5109 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR100","doi-asserted-by":"publisher","first-page":"a5039","DOI":"10.1200\/JCO.2008.20.5450","volume":"27","author":"JR Merchan","year":"2009","unstructured":"Merchan, J. R. et al. Phase I\/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients [abstract]. J. Clin. Oncol. 27, a5039 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR101","doi-asserted-by":"crossref","unstructured":"Houghton, P. Targeting the IGF-1\/mTOR pathway. AACR Meeting Abstracts 2008, PL05\u201303 (2008).","DOI":"10.1158\/AACR.EDB-08-8182"},{"key":"BFnrclinonc201021_CR102","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/AACR.EDB-08-435","volume":"2008","author":"RT Kurmasheva","year":"2008","unstructured":"Kurmasheva, R. T., Easton, J. B. & Houghton, P. J. Combined targeting of mTOR and the insulin-like growth factor pathway. ASCO Educational Book 2008, 460\u2013464 (2008).","journal-title":"ASCO Educational Book"},{"key":"BFnrclinonc201021_CR103","doi-asserted-by":"crossref","first-page":"a10615","DOI":"10.1200\/jco.2007.25.18_suppl.10615","volume":"25","author":"HM McDaid","year":"2007","unstructured":"McDaid, H. M. et al. Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation [abstract]. J. Clin. Oncol. 25, a10615 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR104","doi-asserted-by":"publisher","first-page":"a20033","DOI":"10.1200\/jco.2008.26.15_suppl.20033","volume":"26","author":"F Meier","year":"2008","unstructured":"Meier, F. et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells [abstract]. J. Clin. Oncol. 26, a20033 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR105","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.4161\/cc.7.24.7244","volume":"7","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A., Baselga, J. & Pandolfi, P. P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7, 3805\u20133809 (2008).","journal-title":"Cell Cycle"},{"key":"BFnrclinonc201021_CR106","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909\u2013918 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR107","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/cncr.24280","volume":"115","author":"RJ Amato","year":"2009","unstructured":"Amato, R. J., Jac, J., Giessinger, S., Saxena, S. & Willis, J. P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115, 2438\u20132446 (2009).","journal-title":"Cancer"},{"key":"BFnrclinonc201021_CR108","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan, S. et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314\u20135322 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR109","doi-asserted-by":"crossref","first-page":"a7616","DOI":"10.1200\/jco.2006.24.18_suppl.7616","volume":"24","author":"SS Farag","year":"2006","unstructured":"Farag, S. S. et al. Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results [abstract]. J. Clin. Oncol. 24, a7616 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201021_CR110","first-page":"a4523","volume":"104","author":"KWL Yee","year":"2004","unstructured":"Yee, K. W. L. et al. A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias [abstract]. Blood (ASH Annual Meeting Abstracts) 104, a4523 (2004).","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.21","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:05:18Z","timestamp":1684469118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,16]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BFnrclinonc201021"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.21","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,16]]}}}